

Express Mail Label No.: EV 392131277 US  
Date of Deposit: August 11, 2004

8112104

IFW  
Attorney Docket No.: 23239-531

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Stanton, et al.

SERIAL NUMBER : 10/600,007 EXAMINER : Not Yet Assigned

FILING DATE : June 18, 2003 ART UNIT : 1645

FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING  
SAME

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: A3-8; B1-7; C2-39; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-531. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Jennifer A. Karnakis, Reg. No. 53,097

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.


Address all written correspondence to

**Customer no.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: August 11, 2004



Express Mail Label No.: EV 392131277 US

Date of Deposit: August 11, 2004

Attorney Docket No.: 23239-531

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Stanton, et al.  
SERIAL NUMBER : 10/600,007 EXAMINER : Not Yet Assigned  
FILING DATE : June 18, 2003 ART UNIT : 1645  
FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING SAME

### Mail Stop Amendment

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Stanton, et al.  
U.S.S.N.: 10/600,007

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-531.

Respectfully submitted,




---

Ivor R. Elrifi, Reg. No. 39,529  
Jennifer A. Karnakis, Reg. No. 53,097  
Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: August 11, 2004

TRA 1947189v1



Express Mail Label: EV 392131277 US  
Date of Deposit: August 11, 2004

AUG 11 2004

Please type or plus sign (+) in this box

Page 1 of 2  
Attorney Docket No.: 23239-531

+

Information Disclosure Statement by Applicant  (use as many sheets as necessary)		Application Number	10/600,007
		Filing Date	June 18, 2003
		First Named Inventor	Stanton
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	23239-531

#### U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A3	5,683,867	11/04/97	Biesecker, et al.	435	6	
	A4	5,705,337	01/06/98	Gold, et al.	435	6	
	A5	5,723,594	03/03/98	Janjic, et al.	536	23.1	
	A6	5,834,186	11/10/98	George, et al.	435	6	
	A7	6,083,696	07/04/00	Biesecker, et al.	435	6	
	A8	5,589,332	12/31/96	Shih, et al.	435	6	

#### U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

#### FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 98/08974	INTELLIGENE LTD.	03/05/98	
	B2	WO 98/27104	YALE UNIVERSITY	06/25/98	
	B3	WO 99/31276	NEXSTAR PHARMACEUTICALS, INC.	06/24/99	
	B4	WO 00/70329	BRANDEIS UNIVERSITY	11/23/00	
	B5	WO 01/66721 A2	RIBOZYME PHARMACEUTICALS, INC.	09/13/01	
	B6	WO 02/22882 A2	ARCHEMIX CORPORATION	03/21/02	
	B7	WO 03/014375 A2	ARCHEMIX CORPORATION	02/20/03	

#### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C2	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996).
	C3	Breaker, R.R., <i>Chem. Rev.</i> , 97:371-390 (1997).
	C4	Breaker, R.R., <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997).
	C5	Breaker, R.R., <i>Nat. Biotech.</i> , 15:427-431 (1997).
	C6	Breaker, R.R., Intracellular Ribozyme Applications in Principles and Protocols, pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999).
	C7	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002).
	C8	Carmi, et al. <i>Chem. &amp; Biol.</i> , 3:1039-1046 (1996).
	C9	Gold, L., <i>Nat. Biotech.</i> , 20: 671-672 (2002).
	C10	Hamaguchi, et al., <i>Anal. Biochem.</i> , 294:126-131 (2001).
	C11	Hartig, et al., <i>Nat. Biotech.</i> , 20:717-722 (2002).

C12	Jenne, et al., <i>Nat. Biotech.</i> , 19:56-61 (2001).
C13	Koizumi, et al., <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999).
C14	Koizumi, et al., <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999).
C15	Lewis, et al., <i>Bioconjug. Chem.</i> , 12(2):320-324 (2001).
C16	Li, et al., <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999).
C17	Li, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999).
C18	Marshall, et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999).
C19	Potyrailo, et al., <i>Anal. Chem.</i> , 70:3419-3425 (1998).
C20	Raddatz, et al., <i>Nucl. Acids Res.</i> , 30(21):4793-4802 (2002).
C21	Robertson, et al., <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000).
C22	Robertson, et al., <i>Nat. Biotech.</i> , 17:62-66 (1999).
C23	Robertson, et al., <i>Nat. Biotech.</i> , 19:650-655 (2001).
C24	Sassanfar, et al., <i>Nature</i> , 364:550-553 (1993).
C25	Seetharaman, et al., <i>Nat. Biotech.</i> , 19:336-341 (2001).
C26	Seiwert, et al., <i>Chem. &amp; Biol.</i> , 7:833-843 (2000).
C27	Soukup, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999).
C28	Soukup, et al., <i>RNA</i> , 5:1308-1325 (1999).
C29	Soukup, et al., <i>Structure</i> , 7(7):783-791 (1999).
C30	Soukup, et al., <i>Tren. Biotech.</i> , 17:469-476 (1999).
C31	Soukup, et al., in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds.
C32	Soukup, et al., <i>RNA</i> , 7:524-536 (2001).
C33	Soukup, et al., <i>J. Mol. Biol.</i> , 298:623-632 (2000).
C34	Stetsenko, et al., <i>Nucleosides, Nucleotides &amp; Nucl. Acids</i> , 19(10-12):1751-1764 (2000).
C35	Tang, et al., <i>Chem. &amp; Biol.</i> , 4:453-459 (1997).
C36	Tang, et al., <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998).
C37	Tang, et al., <i>RNA</i> , 3:914-925 (1997).
C38	Trail, et al., <i>Cancer Immunol. Immunother.</i> , 52(5):328-337 (2003).
C39	Tung, C.H., <i>Bioconjug. Chem.</i> , 11(5):605-618 (2000).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.